Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 28;45(1):10.
doi: 10.1007/s00296-024-05763-6.

Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers

Oznur Sadioglu Cagdas  1 , Neslihan Gokcen  2 , Ayten Yazici  2 , Ayse Cefle  2
Affiliations

Monitoring disease activity and treatment response in ankylosing spondylitis: a retrospective study of hematologic inflammatory markers

Oznur Sadioglu Cagdas et al. Rheumatol Int. .

Abstract

Background: Hematological markers such as the neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), and platelet-lymphocyte ratio (PLR) are reliable indicators of inflammation. This study aims to investigate the potential role of these markers in assessing disease activity and treatment response in biologic-naive Ankylosing Spondylitis (AS) patients following the initiation of biological agents.

Materials and methods: We designed this study as a retrospective cohort study with data obtained from a single center. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and The Bath Ankylosing Spondylitis Functional Index (BASFI) were used to evaluate disease activity and functional status of AS patients. Laboratory results at baseline, 3rd, 6th, and 12th months were documented. We calculated hematologic inflammatory markers for each visit. Mean platelet volume (MPV) and red cell distribution width (RDW) were also noted.

Results: 54 biologic-naive patients with AS were included in this study. These inflammatory markers, except RDW, decreased over time. BASDAI, BASFI, CRP and ESR were significantly lower at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). Furthermore, NLR, PLR, and MLR showed a statistically significant decrease at 3rd, 6th, and 12th months compared to baseline values (all p < 0.001). However, when comparing the values at the 3rd, 6th, and 12th months, no statistically significant differences were observed. We also found no correlation between hematological inflammatory markers and BASDAI scores, despite observing some correlations between hematological markers and acute phase reactants.

Conclusion: These markers could be valuable assessment tools for indicating disease activity and monitoring patients with AS after initiating biological treatment.

Keywords: Ankylosing spondylitis (AS); Monocyte-lymphocyte ratio (MLR); Neutrophil-lymphocyte ratio (NLR); Platelet-lymphocyte ratio (PLR); TNF inhibitors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no conflicts of interest regarding the publication of this article.

Similar articles

See all similar articles

References

    1. Kim SH, Lee SH (2023) Updates on ankylosing spondylitis: pathogenesis and therapeutic agents. J Rheum Dis 30(4):220–233. https://doi.org/10.4078/jrd.2023.0041 - DOI - PubMed - PMC
    1. Ebrahimiadib N, Berijani S, Ghahari M, Pahlaviani FG (2021) Ankylosing spondylitis. J Ophthalmic Vis Res 16(3):462–469. https://doi.org/10.18502/jovr.v16i3.9440 - DOI - PubMed - PMC
    1. Coskun Benlidayi I (2023) Bone health in autoimmune inflammatory rheumatic diseases. In: Rezaei N (ed) Translational Immunology, Translational Autoimmunity. Elsevier Inc., Academic Press. https://doi.org/10.1016/b978-0-323-85831-1.00002-4
    1. Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A et al (2019) 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71(10):1599–1613. https://doi.org/10.1002/art.41042 - DOI - PubMed - PMC
    1. Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewé RBM, Van den Bosch FE, Boteva B, Bremander A et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19–34. https://doi.org/10.1136/ard-2022-223296 - DOI - PubMed

LinkOut - more resources